• Marcelo Trivi, Nicolás Lalor, Pablo Spaletra, Alesis Raffaeli, Juan Costabel, and Jorge Belardi.
• Instituto Cardiovascular de Buenos Aires (ICBA), Buenos Aires, Argentina. E-mail: mstrivi@icba.com.ar.
• Medicina (B Aires). 2020 Jan 1; 80 Suppl 6: 97-99.

AbstractCoronary involvement in COVID-19 infection usually presents as type 2 acute myocardial infarction (AMI), due to increased 02 consumption and reduction of oxygen supply, and less frequently as type 1 (STEMI). In that cases, thrombogenicity of the infection may contribute to acute coronary occlusion. We present 2 cases of middle-aged men, with few or none cardiovascular risk factors, who were in hospital during 10 days because pneumonia due to COVID-19 with good evolution. In the convalescent phase, one day after hospital discharge, and enoxaparin suspension, they went back to hospital because STEMI. Both were treated by direct angioplasty using pharmacologic stent. Discussion is related to treatment of AMI at discharge, if anticoagulation should be added to double antiplatelet therapy, and if any prophylactic antithrombotic treatment should be considered at discharge from COVID-19 pneumonia in some patients.

13 keywords...

hide…